This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (70)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A New Approach to Staging and Treatment

Sydney E. Salmon, MD; Brian G. M. Durie, MD

Arch Intern Med. 1975;135(1):131-138.

Abstract
Previous studies of myeloma immunoglobulin synthesis and tumor cell number, using a marker kinetic approach, have increased knowledge about body burden of tumor cells, kinetics of myeloma cell growth, and response to chemotherapy. On the basis of these observations, we have developed a clinical staging system that permits accurate estimation of total myeloma cell number in patients who have not had specialized immunosynthetic measurements. We have incorporated this clinical staging into a nationwide time-sharing computer network called the Myeloma Study System (MSS). With the MSS we are able to establish a file for each patient, keep track of changes in tumor cell number with treatment, and evaluate toxicity. This resource should afford an excellent test of the value of cellular kinetics for the planning and uniform evaluation of cancer chemotherapy.

Author Affiliations
From the Section of Hematology and Oncology, Department of Internal Medicine, University of Arizona College of Medicine, Tucson.

Footnotes
Received for publication March 7, 1974; accepted May 16.

Read before the Symposium on Myeloma, Atlanta, Oct 22, 1973.

Reprint requests to 1501 N Campbell Ave, Tucson, AZ 85724 (Dr. Salmon).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial
Sonneveld et al.
haematol 2007;92:928-935.
ABSTRACT | FULL TEXT  

Donor Lymphocyte Infusions for Relapsed Multiple Myeloma After Allogeneic Stem-Cell Transplantation: Predictive Factors for Response and Long-Term Outcome
Lokhorst et al.
JCO 2000;18:3031-3037.
ABSTRACT | FULL TEXT  

Plasma Cell Dyscrasias and Cryoglobulins
Bloch and Franklin
JAMA 1982;248:2670-2676.
ABSTRACT  

Multiple Myeloma in a Young Person
Kohli and Vladutiu
JAMA 1978;239:295-296.
ABSTRACT